Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sexually Transmitted Infections (STI) Clear all
Recruiting Phase 3 Interventional

V+PSF-M for Tobacco Cessation in HIV Care in India

NCT05786547
View directory record Official record
Conditions
Human Immunodeficiency Virus, Smoking Cessation, Smoking, Tobacco
Interventions
Varenicline, Positively Smoke Free Mobile (PSF-M), Standard Care
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Early Phase 1 Interventional

Non Invasive Oral Cancer Screening Among HIV Infected Individuals

NCT02823847
View directory record Official record
Conditions
Malignant Neoplasms of Mesothelial and Soft Tissue, Human Immunodeficiency Virus
Interventions
Screening Interview, Carbon Monoxide Test, Self-Help Materials, Visual Oral Screening Examination, Direct Fluorescent Oral Visualization Examination, Oral Biopsy
Behavioral · Device · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

NCT00459316
View directory record Official record
Conditions
HIV Infections, Meningitis
Interventions
Quadrivalent meningococcal conjugate vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 24 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
35
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception

NCT01667978
View directory record Official record
Conditions
Pregnancy, HIV, AIDS
Interventions
Norethindrone acetate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Phase 4 Interventional

Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS

NCT01158443
View directory record Official record
Conditions
Hiv, Fatigue, Goals
Interventions
Behavioral Activation Therapy, Supportive Counseling
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Phase 2 Interventional

A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients

NCT00002435
View directory record Official record
Conditions
HIV Infections
Interventions
Thymic Humoral Factor, Zidovudine
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Not applicable Interventional

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC)

NCT00002060
View directory record Official record
Conditions
HIV Infections
Interventions
Inosine pranobex
Drug
Lead sponsor
Newport Pharmaceuticals International
Industry
Eligibility
18 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions

NCT01132716
View directory record Official record
Conditions
Herpes Zoster, Shingles, Genital Herpes
Interventions
Valacyclovir Hydrochloride
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jun 10, 2026, 10:50 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients

NCT00504452
View directory record Official record
Conditions
HIV Infections
Interventions
KP-1461
Drug
Lead sponsor
Koronis Pharmaceuticals.
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
30
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Phase 2 Interventional

A Phase II/III Study of Cysteamine (Mercaptoethylamine) and Zidovudine for the Treatment of HIV Disease

NCT00002110
View directory record Official record
Conditions
HIV Infections
Interventions
Cysteamine, Zidovudine
Drug
Lead sponsor
Mylan Laboratories
Industry
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Tampa, Florida • New Orleans, Louisiana • Stony Brook, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 10:50 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The Dreamer Girls Project: Adaptation of SISTA/SIHLE for HIV/AIDS and Substance Abuse Prevention Among Black Adolescent Girls

NCT05014074
View directory record Official record
Conditions
HIV/AIDS
Interventions
Theater/Pilot Testing
Other
Lead sponsor
Yale University
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Paterson, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Not applicable Interventional

Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV Medication Adherence

NCT05783297
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment Text (TXTXT), Standard of Care
Behavioral
Lead sponsor
Amy K. Johnson, PhD, MSW
Other
Eligibility
16 Years to 35 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Fort Lauderdale, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Not applicable Interventional

Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center

NCT00267410
View directory record Official record
Conditions
Sexually Transmitted Diseases, HIV Infections
Interventions
Healthy Relationships
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 24 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract

NCT03917420
View directory record Official record
Conditions
HIV/AIDS
Interventions
Tenofovir 300Mg Oral Tablet, Emtricitabine 200 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers

NCT00000868
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults

NCT03721510
View directory record Official record
Conditions
HIV/AIDS
Interventions
PGT121 + VRC07-523LS, PGT121 + VRC07-523LS + PGDM1400
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
3
States / cities
Orlando, Florida • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Phase 3 Interventional

A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3

NCT00002123
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Didanosine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
83
States / cities
Birmingham, Alabama • Berkeley, California • Fresno, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 10:50 AM EDT
Active, not recruiting Early Phase 1 Interventional

Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix

NCT07182838
View directory record Official record
Conditions
HIV Infections
Interventions
HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use
Biological
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Industry
Eligibility
24 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Phase 2Phase 3 Interventional

TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB

NCT00023348
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Rifabutin
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2005 · Synced Jun 10, 2026, 10:50 AM EDT
Withdrawn Not applicable Interventional

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

NCT00006578
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir, Lamivudine, Filgrastim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Denver, Colorado • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Jun 10, 2026, 10:50 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV

NCT06557785
View directory record Official record
Conditions
HIV Infections
Interventions
CH505M5 N197D mRNA-gp160, CH505 TF mRNA-gp160
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

NCT00001108
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Nevirapine, Lamivudine, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 22 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 10, 2026, 10:50 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up

NCT03275350
View directory record Official record
Conditions
Opioid-use Disorder, Hiv
Interventions
Naltrexone Injectable Suspension, Treatment as usual
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Tarzana, California • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Jun 10, 2026, 10:50 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
9vHPV Vaccine, Placebo (Saline for Injection)
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
6,033 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
32
States / cities
Northridge, California • Rialto, California • Simi Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Jun 10, 2026, 10:50 AM EDT